Fate Therapeutics (FATE)

$1.04 -0.06 (-5.45%)
Market Cap 126.06M
Revenue (ttm) 13.63M
Net Income (ttm) -186.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,366.54%
Debt to Equity Ratio 0.00
Volume 3,748,200
Avg Vol 2,023,836
Day's Range N/A - N/A
Shares Out 114.60M
Stochastic %K 5%
Beta 2.23
Analysts Sell
Price Target $5.62

Company Profile

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus eryt...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 875 1800
Address:
12278 Scripps Summit Drive, San Diego, United States
Peterson28
Peterson28 Jun. 28 at 7:10 AM
$FATE Down 40% from the position I sold. I will gradually buy back in.
0 · Reply
KNCourt24
KNCourt24 Jun. 27 at 8:11 PM
$FATE 2.4mill green candle…
0 · Reply
Rocketman808
Rocketman808 Jun. 27 at 6:31 PM
$FATE touch penny again. i dare you
0 · Reply
KNCourt24
KNCourt24 Jun. 27 at 6:16 PM
$FATE I’ll avg down at these gift prices.
0 · Reply
KNCourt24
KNCourt24 Jun. 26 at 4:48 PM
$FATE Holding long this will be $5+ soon. Big Institutions loading up at levels and already have 63% of the float locked. Retail control less than 15% buy and hold for that short squeeze rocket
3 · Reply
Rocketman808
Rocketman808 Jun. 26 at 4:42 PM
$FATE accumulation. expecting a quiet 3 months, and build up in the last few months this year starting Sept. rate cuts/general market moves will fuel moves until then
0 · Reply
Anakin06
Anakin06 Jun. 26 at 1:43 PM
$FATE not bullish at all what this should be bullish ?
0 · Reply
KNCourt24
KNCourt24 Jun. 26 at 1:23 PM
$FATE
0 · Reply
Jake140
Jake140 Jun. 26 at 11:24 AM
$FATE
0 · Reply
Rocketman808
Rocketman808 Jun. 26 at 4:14 AM
$FATE
0 · Reply
Latest News on FATE
Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

Jun 11, 2025, 9:00 AM EDT - 16 days ago

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

May 30, 2025, 4:30 PM EDT - 4 weeks ago

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

May 28, 2025, 5:54 PM EDT - 4 weeks ago

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

May 13, 2025, 4:01 PM EDT - 6 weeks ago

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector

May 8, 2025, 6:22 PM EDT - 7 weeks ago

Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

May 2, 2025, 4:01 PM EDT - 2 months ago

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

Apr 29, 2025, 9:25 AM EDT - 2 months ago

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

Apr 14, 2025, 8:00 AM EDT - 2 months ago

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 5, 2025, 4:01 PM EST - 4 months ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Mar 4, 2025, 4:01 PM EST - 4 months ago

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics to Present at Upcoming Investor Conferences

Feb 14, 2025, 4:01 PM EST - 4 months ago

Fate Therapeutics to Present at Upcoming Investor Conferences

Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap

Feb 4, 2025, 7:41 PM EST - 5 months ago

Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

Dec 9, 2024, 4:01 PM EST - 7 months ago

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

Fate Therapeutics Announces Leadership Transition

Nov 29, 2024, 1:05 PM EST - 7 months ago

Fate Therapeutics Announces Leadership Transition

Fate Therapeutics to Present at Upcoming December Investor Conferences

Nov 26, 2024, 4:01 PM EST - 7 months ago

Fate Therapeutics to Present at Upcoming December Investor Conferences

Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options

Nov 20, 2024, 4:34 PM EST - 7 months ago

Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

Nov 18, 2024, 8:05 AM EST - 7 months ago

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

Nov 12, 2024, 4:01 PM EST - 8 months ago

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

Nov 9, 2024, 1:30 PM EST - 8 months ago

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

Nov 8, 2024, 4:01 PM EST - 8 months ago

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Sep 12, 2024, 4:01 PM EDT - 10 months ago

Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

Aug 13, 2024, 4:05 PM EDT - 11 months ago

Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

May 29, 2024, 4:01 PM EDT - 1 year ago

Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call Transcript

May 11, 2024, 6:12 PM EDT - 1 year ago

Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call Transcript

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

May 9, 2024, 4:01 PM EDT - 1 year ago

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

May 9, 2024, 8:30 AM EDT - 1 year ago

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

May 3, 2024, 4:30 PM EDT - 1 year ago

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

Fate Therapeutics: As Its Rally Fizzles, We May Be Near The Bottom

Apr 29, 2024, 4:48 PM EDT - 1 year ago

Fate Therapeutics: As Its Rally Fizzles, We May Be Near The Bottom

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Apr 29, 2024, 12:09 PM EDT - 1 year ago

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

Apr 22, 2024, 4:30 PM EDT - 1 year ago

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

Mar 19, 2024, 8:44 AM EDT - 1 year ago

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

Fate Therapeutics to Present at Upcoming March Investor Conferences

Mar 1, 2024, 8:00 AM EST - 1 year ago

Fate Therapeutics to Present at Upcoming March Investor Conferences

Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 8:25 PM EST - 1 year ago

Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript

Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Feb 26, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

Feb 15, 2024, 8:00 AM EST - 1 year ago

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 13, 2023, 5:00 PM EST - 1 year ago

Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics: Getting There, But Perpetually

Nov 12, 2023, 12:10 PM EST - 1 year ago

Fate Therapeutics: Getting There, But Perpetually

Fate Therapeutics, Inc. (FATE) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 9:12 PM EST - 1 year ago

Fate Therapeutics, Inc. (FATE) Q3 2023 Earnings Call Transcript

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Nov 8, 2023, 4:01 PM EST - 1 year ago

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

Oct 25, 2023, 8:00 AM EDT - 1 year ago

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

Fate Therapeutics to Present at Upcoming September Investor Conferences

Aug 31, 2023, 8:00 AM EDT - 1 year ago

Fate Therapeutics to Present at Upcoming September Investor Conferences

Fate Therapeutics, Inc. (FATE) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 11:37 PM EDT - 2 years ago

Fate Therapeutics, Inc. (FATE) Q2 2023 Earnings Call Transcript

Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results

Jul 28, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results

Fate Therapeutics to Present at Upcoming June Investor Conferences

May 31, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Present at Upcoming June Investor Conferences

Fate Therapeutics: The Future Remains Cloudy

May 23, 2023, 1:40 PM EDT - 2 years ago

Fate Therapeutics: The Future Remains Cloudy

Fate Therapeutics, Inc. (FATE) Q1 2023 Earnings Call Transcript

May 3, 2023, 8:34 PM EDT - 2 years ago

Fate Therapeutics, Inc. (FATE) Q1 2023 Earnings Call Transcript

Peterson28
Peterson28 Jun. 28 at 7:10 AM
$FATE Down 40% from the position I sold. I will gradually buy back in.
0 · Reply
KNCourt24
KNCourt24 Jun. 27 at 8:11 PM
$FATE 2.4mill green candle…
0 · Reply
Rocketman808
Rocketman808 Jun. 27 at 6:31 PM
$FATE touch penny again. i dare you
0 · Reply
KNCourt24
KNCourt24 Jun. 27 at 6:16 PM
$FATE I’ll avg down at these gift prices.
0 · Reply
KNCourt24
KNCourt24 Jun. 26 at 4:48 PM
$FATE Holding long this will be $5+ soon. Big Institutions loading up at levels and already have 63% of the float locked. Retail control less than 15% buy and hold for that short squeeze rocket
3 · Reply
Rocketman808
Rocketman808 Jun. 26 at 4:42 PM
$FATE accumulation. expecting a quiet 3 months, and build up in the last few months this year starting Sept. rate cuts/general market moves will fuel moves until then
0 · Reply
Anakin06
Anakin06 Jun. 26 at 1:43 PM
$FATE not bullish at all what this should be bullish ?
0 · Reply
KNCourt24
KNCourt24 Jun. 26 at 1:23 PM
$FATE
0 · Reply
Jake140
Jake140 Jun. 26 at 11:24 AM
$FATE
0 · Reply
Rocketman808
Rocketman808 Jun. 26 at 4:14 AM
$FATE
0 · Reply
KNCourt24
KNCourt24 Jun. 25 at 8:48 PM
$FATE big accumulation going on at these levels. Past week big volume right at close consistently👀
0 · Reply
KNCourt24
KNCourt24 Jun. 24 at 3:37 PM
$FATE Reversal imminent at these levels
2 · Reply
KNCourt24
KNCourt24 Jun. 23 at 8:27 PM
$FATE Been some big buys past few days right after market close👀
0 · Reply
KNCourt24
KNCourt24 Jun. 23 at 1:56 PM
$FATE overdue for a reversal that 1.80 was just the start
0 · Reply
KNCourt24
KNCourt24 Jun. 23 at 2:46 AM
$FATE
0 · Reply
Ned_Nosurname
Ned_Nosurname Jun. 21 at 10:07 PM
$FATE A new preclinical paper https://pubmed.ncbi.nlm.nih.gov/40541190/
1 · Reply
KNCourt24
KNCourt24 Jun. 20 at 8:10 PM
$FATE Huge buys AH👀
0 · Reply
KNCourt24
KNCourt24 Jun. 20 at 7:33 PM
$FATE Under $2 is a gift with this. Majority big intuitional holdings. Buyout or partnership could happen anytime. Sleeping giant
0 · Reply
Rocketman808
Rocketman808 Jun. 20 at 6:32 PM
$FATE looks like accumulation
0 · Reply
KNCourt24
KNCourt24 Jun. 20 at 5:47 PM
$FATE Great buy at these levels added some here
0 · Reply
GenerallyGentle
GenerallyGentle Jun. 20 at 2:58 PM
$FATE dont mind if I do ... added 1.21.
0 · Reply
Jake140
Jake140 Jun. 20 at 11:14 AM
$FATE
0 · Reply